Published in Br J Haematol on March 01, 1975
Prothrombin is activated on vascular endothelial cells by factor Xa and calcium. Proc Natl Acad Sci U S A (1983) 2.06
Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J Clin Invest (1978) 1.42
Subcellular localization and secretion of factor V from human platelets. Proc Natl Acad Sci U S A (1981) 1.09
Human coagluation factor V purification and thrombin-catalyzed activation. J Clin Invest (1980) 1.05
High-molecular weight kininogen. A secreted platelet protein. J Clin Invest (1983) 1.03
Activation of coagulation factor V by a platelet protease. J Clin Invest (1982) 0.89
Platelet C1- inhibitor. A secreted alpha-granule protein. J Clin Invest (1985) 0.89
Biosynthesis of factor V in isolated guinea pig megakaryocytes. J Clin Invest (1985) 0.85
Human platelets and factor XI. Localization in platelet membranes of factor XI-like activity and its functional distinction from plasma factor XI. J Clin Invest (1979) 0.80
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med (1992) 3.74
Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med (1997) 3.26
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet (1988) 2.67
Factor 8 on the vascular intima: possible importance in haemostasis and thrombosis. Nat New Biol (1973) 2.43
A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med (1993) 2.39
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Increased factor IX levels in puerperium during administration of diethylstilboestrol. Br Med J (1968) 2.29
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet (1997) 2.20
Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet (1994) 2.18
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med (1990) 2.05
[Atherosclerosis partly due to local vasculitis]. Ned Tijdschr Geneeskd (1994) 2.05
[Optimal treatment with oral anticoagulants]. Ned Tijdschr Geneeskd (1996) 2.03
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation (1992) 1.78
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med (1990) 1.76
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet (1994) 1.76
Carrier detection by direct gene analysis in a family with haemophilia B (factor IX deficiency). Lancet (1984) 1.74
Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis (1992) 1.73
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73
Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med (1996) 1.70
Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med (1999) 1.64
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (1994) 1.63
Reliable rapid blood test for the exclusion of venous thromboembolism in symptomatic outpatients. Thromb Haemost (1996) 1.61
The value of lung scintigraphy in the diagnosis of pulmonary embolism. Eur J Nucl Med (1993) 1.61
Intestinal endotoxemia. Clinical significance. Gastroenterology (1988) 1.59
Antigen biological activity ratio for factor VIII in late pregnancy. Lancet (1973) 1.54
Review: infectious diseases and coagulation disorders. J Infect Dis (1999) 1.50
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
STRAIN ELECTROMETRY AND CORROSION I. GENERAL CONSIDERATIONS ON INTERFACIAL ELECTRICAL TRANSIENTS. Proc Natl Acad Sci U S A (1957) 1.39
[Deep venous thrombosis: does recently improved knowledge lead to a real advance in the direction patient care?]. Ned Tijdschr Geneeskd (1996) 1.39
Additive effect of dDAVP and standard heparin in increasing plasma t-PA. Thromb Haemost (1989) 1.39
[High-density lipoproteins]. Ned Tijdschr Geneeskd (1992) 1.38
[Diagnostic management in suspicion of pulmonary embolism: results of a survey among Dutch internists and pulmonologists]. Ned Tijdschr Geneeskd (1992) 1.38
[Antifibrinolytic therapy]. Ned Tijdschr Geneeskd (1995) 1.38
Inherited variants of factor-VIII-related protein in von Willebrand's disease. N Engl J Med (1974) 1.36
Failure of computerized impedance plethysmography in the diagnostic management of patients with clinically suspected deep-vein thrombosis. Thromb Haemost (1991) 1.32
Postoperative problems and management after hepatic resection for blunt injury to the liver. Br J Surg (1975) 1.30
A new computerized impedance plethysmograph: accuracy in the detection of proximal deep-vein thrombosis in symptomatic outpatients. Thromb Haemost (1991) 1.29
Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood (1994) 1.28
Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med (1992) 1.27
Flow-field-flow fractionation: a versatile new separation method. Science (1976) 1.26
Two-dimensional separations: concept and promise. Anal Chem (1984) 1.24
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol (1997) 1.21
Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest (1989) 1.20
Rapid diffusion coefficient measurements using analytical SPLITT fractionation: application to proteins. Anal Biochem (1993) 1.20
The von Willebrand syndrome. Semin Hematol (1980) 1.19
Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood (1992) 1.17
A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol (1972) 1.14
Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery (1993) 1.13
Electrical field-flow fractionation of proteins. Science (1972) 1.13
Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol (1988) 1.13
Facile and rapid analysis of three DNA polymorphisms within the human factor IX gene using the polymerase chain reaction. Br J Haematol (1991) 1.13
Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients. J Clin Invest (1987) 1.12
Inherited thrombocytopenia, elevated serum IgA and renal disease: identification as a variant of the Wiskott-Aldrich syndrome. Q J Med (1986) 1.12
HTLV-III antibody status and immunological abnormalities in haemophilic patients. Lancet (1985) 1.12
Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med (1991) 1.11
Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost (1996) 1.09
[Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo]. Ned Tijdschr Geneeskd (1993) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
Properties of an asymmetrical flow field-flow fractionation channel having one permeable wall. Anal Chem (1987) 1.07
Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol (1971) 1.07
Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood (1997) 1.06
Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol (1989) 1.05
Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis (1993) 1.05
Intravascular coagulation and the liver. Br J Haematol (1975) 1.04
The clinical course of patients with suspected pulmonary embolism. Arch Intern Med (1998) 1.04
Differential localisation and synthesis of porcine factor VIII related antigen (VIIIR:AG) in vascular endothelium and in endothelial cells in culture. Thromb Res (1983) 1.02
Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med (1986) 1.02
Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost (1998) 1.01
Quantitative endotoxin determination in blood with a chromogenic substrate. Clin Chim Acta (1981) 1.01
The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost (1996) 1.01
Immunological studies in combined factor V and factor VIII deficiency. Br J Haematol (1977) 1.00
The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br J Haematol (1984) 1.00
Rapid protein separation and diffusion coefficient measurement by frit inlet flow field-flow fractionation. Protein Sci (1993) 0.99
Coagulopathy in Ruptured or Dissecting Aortic Aneurysms. Am J Med (1975) 0.98
Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem (1988) 0.98
Changes in Blood After Using an Extracorporeal Circulation. Br Med J (1961) 0.97
Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood (1997) 0.97
Defibrination syndrome with defective thrombinfibrinogen reaction reversible by protamine. J Clin Pathol (1965) 0.97
Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma. Eur Urol (1984) 0.97
Carrier detection in 50 haemophilia A kindred by means of three intragenic and two extragenic restriction fragment length polymorphisms. Br J Haematol (1988) 0.97
A study of cell mediated and humoral immunity in haemophilia and related disorders. Br J Haematol (1985) 0.97
Effect of O-(beta-hydroxyethyl)-rutoside on red cell and platelet functions in man. Bibl Anat (1973) 0.97
Tentative protocol for the evaluation of coagulometers, based on one-stage prothrombin time. Clin Lab Haematol (1981) 0.97
Linked and intragenic probes for haemophilia A. Lancet (1985) 0.96
Detection and clinical relevance of human endotoxemia. Z Med Lab Diagn (1990) 0.96
Immunoradiometric assay of procoagulant factor-VIII antigen in plasma and serum and its reduction in haemophilia. Preliminary studies on adult and fetal blood. Lancet (1978) 0.96
Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol (1995) 0.96
Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost (1995) 0.95
Fractionating power in programmed field-flow fractionation: exponential sedimentation field decay. Anal Chem (1987) 0.95